Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-522 · 7 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55) |
| 2 | OTHER | Docetaxel + Prednisone + Zoledronic Acid (N=55) |
| MEDI-522 | EXPERIMENTAL | Drug |
| 3 | EXPERIMENTAL | MEDI-522 |
| 4 | EXPERIMENTAL | MEDI-522 |
| 5 | EXPERIMENTAL | MEDI-522 |
| Name | Type | Description |
|---|---|---|
| MEDI-522 | BIOLOGICAL | IV at a concentration of 50 mg/mL and 10mL vials |
| Docetaxel + Prednisone* + Zoledronic Acid | BIOLOGICAL | IV 75 mg/m2 IV 3-4 mg 5 mg |
| Placebo | OTHER | 4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0) |
| MEDI--522 | BIOLOGICAL | IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL. |
| Integrin + Dacarbazine | BIOLOGICAL | supplied in other formulations |
Inclusion Criteria: * Adult men at least 18 years of age at the time of randomization. * Metastatic, histologically or cytologically confirmed adenocarcinoma of the prostate that has progressed after start of androgen deprivation therapy, which includes prior orchiectomy or medical castration using...
Top 20 of 52 competitors
MEDI-522 is an investigational small molecule being developed by AstraZeneca PLC for cancer and inflammatory conditions. It has been studied in solid tumors including colorectal cancer and malignant melanoma, as well as in plaque psoriasis. Development has remained at the Phase 1 stage for the oncology programs.
MEDI-522 has been studied in cancer, including irinotecan-refractory advanced colorectal cancer, refractory solid tumors, and advanced malignant melanoma. It has also been evaluated in plaque psoriasis. Listed indications for the program also include prostate cancer and rheumatoid arthritis, though clinical trials have focused on cancer and psoriasis.
MEDI-522 is developed by AstraZeneca PLC, which trades under the ticker AZN. The drug was studied across Phase 1 oncology trials in the United States and France, and in a Phase 2 plaque psoriasis study conducted in the United States and Canada.
MEDI-522 is in Phase 1 development for its oncology indications. The program has also included a Phase 2 trial in plaque psoriasis. MEDI-522 is investigational and has not been approved by the FDA for any indication.
MEDI-522 has been evaluated in completed trials including NCT00284817 in irinotecan-refractory advanced colorectal cancer, NCT00263783 in refractory solid tumors, NCT00192517 in plaque psoriasis, and NCT00111696 in advanced malignant melanoma. All four studies are completed, and no MEDI-522 trials are currently active.
Yes, MEDI--522 is an alternative spelling of MEDI-522. Both names refer to the same investigational small molecule developed by AstraZeneca PLC. The drug has also appeared under the name Abergrin in a Phase 1 study of advanced malignant melanoma.